The Immune System and Depression: What the Research Now Shows

Medically reviewed by Tracy McCarthy, MD — Board-Certified Psychiatrist, IFM-Certified Functional Medicine Practitioner

A Model That Was Incomplete

For several decades, the dominant explanation of depression was neurochemical: not enough serotonin, dopamine, or norepinephrine in the space between brain cells. The treatments that followed from this model were logically consistent — medications designed to increase the availability of these neurotransmitters in the brain.

The model was not wrong. It was incomplete.

A substantial and growing body of research now points to the immune system — specifically to a process called neuroinflammation — as a significant contributor to how depression develops and persists in a meaningful number of people. This is not a fringe hypothesis. It is the foundation of an emerging area of medicine called immunopsychiatry, and it is actively changing how depression is understood and approached clinically.

What Neuroinflammation Does to the Brain

Neuroinflammation refers to an inflammatory process that occurs within the brain and nervous system, involving the activation of the brain's resident immune cells — called microglia — and the release of inflammatory chemicals into the brain tissue.

A comprehensive review published in Brain Sciences (https://pmc.ncbi.nlm.nih.gov/articles/PMC12024626/) describes how these inflammatory processes affect the hippocampus, amygdala, and prefrontal cortex — the parts of the brain most directly involved in mood regulation, decision-making, and stress response. Inflammation in these areas impairs neuroplasticity, reduces the brain's ability to generate new neurons, and disrupts the signaling that regulates emotional experience.

There is also a specific chemical pathway connecting inflammation and serotonin that is worth understanding. When inflammatory chemicals called cytokines are elevated, they activate an enzyme that redirects the amino acid tryptophan — the raw material for serotonin — away from serotonin production and toward a different pathway. The result is both reduced serotonin availability and the production of compounds that are directly toxic to neurons and that sustain the inflammatory state. This is why, for some people, depression driven primarily by inflammation does not respond well to medications targeting serotonin reuptake. The issue is not downstream of the synapse. It is upstream of serotonin production entirely.

Where the Inflammation Comes From

The body's inflammatory state crosses into the brain through multiple routes: a disrupted gut barrier that allows bacterial components into the bloodstream, signaling through the vagus nerve, and immune cells moving from the periphery into the central nervous system.

A review published in Cells (https://www.mdpi.com/2073-4409/13/5/423) on inflammatory mechanisms in major depressive disorder identifies how elevated inflammatory chemicals in the body trigger neuroinflammatory processes and gut dysbiosis, which together alter tryptophan metabolism and impair the brain's capacity for neuroplasticity and resilience.

The sources of that peripheral inflammation are varied and often modifiable: gut dysbiosis, insulin resistance, visceral fat, poor sleep, chronic stress, environmental toxin exposures, and diets high in ultra-processed foods. These are not exotic factors. They are common, measurable, and addressable.

What This Means for Treatment

The clinical implication is direct. For individuals whose depression is driven primarily by neuroinflammation, medications that target serotonin reuptake may not be sufficient to reach the upstream driver. They may still help — medications have a place and should not be dismissed — but they may not be addressing the root cause.

A review published in Psychiatry Research (https://pmc.ncbi.nlm.nih.gov/articles/PMC8835211/) on the gut microbiome and depression notes that microbial factors contribute to depressive symptoms through neuroinflammatory pathways and discusses the therapeutic potential of probiotic approaches including bacteria that produce butyrate, a compound that supports the microbiota-gut-brain axis and has been associated with reductions in neuroinflammatory burden.

This is one reason a functional medicine evaluation — which assesses inflammatory burden, gut health, metabolic function, hormones, nutrients, and toxic load — can produce different results than a purely psychiatric evaluation for some individuals. It reaches for different and often more upstream levers.

Who May Have Inflammatory Depression

There is no single blood test that definitively identifies inflammatory depression as a distinct subtype. But certain patterns are associated with higher inflammatory burden and are worth noting:

• Depression that occurs alongside chronic fatigue, widespread pain, or recurrent infections suggests a higher inflammatory component.

• Depression that has not responded adequately to multiple medication trials has been associated in research with elevated inflammatory markers.

• Depression that began or worsened following a significant infection, mold exposure, or period of major physiological stress may reflect an inflammatory trigger.

• Depression with prominent cognitive symptoms like brain fog, word-finding difficulty, memory changes may involve more significant neuroinflammatory pathology.

These are patterns worth raising with a provider who is prepared to investigate the full picture.

Small Steps Worth Considering

• Ask your provider about measuring CRP and other inflammatory markers if this has not been done, these give a preliminary picture of systemic inflammatory burden

• Discuss gut health if digestive symptoms and mood symptoms co-occur — gut dysbiosis is one of the most significant upstream drivers of neuroinflammation

• Evaluate omega-3 fatty acid intake, these have direct anti-inflammatory effects at the neurological level and are frequently insufficient in modern diets

• Address sleep quality as a clinical priority — sleep deprivation is a powerful activator of the neuroinflammatory processes relevant to depression

• Consider asking your provider whether the upstream driver of your mood symptoms has been adequately investigated alongside the downstream neurochemical picture

A Final Thought

The growing research in immunopsychiatry is not a rejection of conventional care. It is an expansion of what the field can offer. And for people who have not found adequate relief through existing approaches, it may represent the most important direction left to explore.

If depression, fatigue, cognitive symptoms, and gut issues are all part of your picture, the Root Cause Health Assessment may help you identify where to begin the investigation.